Vendor Intelligence Report: Kerisite Shenzhen International

Published 3 Jul 2026. 21-page investigative report on who is behind Kerisite Shenzhen International: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Kerisite Shenzhen International is not a one-number vendor. Across 20 Finnrick lab tests (11 pass / 9 fail), the overall pass rate is 55%. The record covers only two products and is uneven: Retatrutide is the more usable Kerisite buy because it has real passing lots, but the report flags material batch variability; Cagrilintide is weaker, with no independent pass in the current authoritative record. Ratings also tighten under stricter methodology, so public pass/fail should not be treated as precision-fill assurance.

The identity record is better than an anonymous chat seller but messier than a mature manufacturer. Investigators found a live Hong Kong company, named sales contacts, mainstream payment options, and an employee-verification tool. They also found three active Kerisite-branded domains telling incompatible origin stories — founded 2019, founded 2023, and 20+ years’ experience — against a much newer verified footprint.

The remaining risk is supply-chain proof. The Hong Kong address is a registration signal, not a verified peptide plant, and public searches did not confirm a mainland manufacturing filing. The dual Hong Kong/U.S. warehouse claim lacks a disclosed U.S. address or fulfillment partner. Reputation is thin: no referral-code network surfaced in searched channels, but suspect positive review pages did.

Inside the full report:

  • Appendix A per-product pass/fail breakdown for both tested products
  • Rating trajectories and methodology-divergence charts
  • Cross-domain timeline for the three Kerisite storefronts
  • Hong Kong company record and registered-address analysis
  • Manufacturing-footprint review of missing mainland factory proof
  • Payment, shipping, warehouse-claim, and reputation-scan exhibits

Risk assessment

  • Retatrutide quality-control risk — high: Retatrutide has 18 Finnrick tests with 11 pass / 7 fail and a 68.62% rating; use only with lot-by-lot verification.
  • Cagrilintide quality-control risk — high: Cagrilintide has 2 Finnrick tests with 0 pass / 2 fail and a 50.35% rating; no independent pass in the current record.
  • Regulatory and customs seizure risk — high: China/Hong Kong peptide fulfillment faces active CBP category scrutiny; Kerisite was not named, but U.S. buyers should verify domestic fulfillment.
  • Marketing-integrity risk — high: Three active domains present conflicting founding narratives against a 2025 verified footprint, and fabricated-looking positive review pages were captured.
  • Channel-verification and brand-confusion risk — medium: Multiple domains, Facebook pages, and phone numbers create ambiguity; the employee verifier helps but no official-channel map was found.
  • Manufacturing-source verification risk — medium: The Hong Kong company is live, but no mainland factory registration, audited facility address, or manufacturing license was verified.